Approved indications: Pavblu (aflibercept-ayyh) is approved for intravitreal treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in adults.

Off-label uses: There are no well-established off-label uses specific to Pavblu; in practice, any off-label use would generally mirror situations where other aflibercept products are used off-label, with evidence extrapolated from Eylea studies rather than dedicated Pavblu trials.

Efficacy expectations: Many patients have reduction in retinal fluid and stabilization or improvement of vision within the first 3 to 6 months of regular injections, and long-term studies of aflibercept products show high rates of maintaining vision over at least 1 to 2 years when the recommended dosing schedule is followed.

Comparison to similar drugs: As a biosimilar to Eylea 2 mg, Pavblu has been shown to have no clinically meaningful differences in quality, safety, or efficacy, and overall outcomes are broadly comparable to other intravitreal anti-VEGF agents (such as ranibizumab or bevacizumab) when used on appropriate treatment regimens.

How Pavblu is given: Pavblu is administered only by an eye specialist as an intravitreal injection (into the vitreous cavity inside the eye) in a clinic or office setting; patients do not self-inject this medicine.

Typical adult dosing by condition:

• Neovascular (wet) age-related macular degeneration (AMD): 2 mg (0.05 mL of 40 mg/mL solution) injected into the affected eye every 4 weeks for the first 3 months, then usually every 8 weeks; after a year of stable control some patients may extend to every 12 weeks, while others may need to remain on every 4- to 8-week dosing.
• Macular edema following retinal vein occlusion (RVO): 2 mg injected into the affected eye once every 4 weeks on an ongoing basis, with the regimen adjusted according to response.
• Diabetic macular edema (DME) and diabetic retinopathy (DR): 2 mg every 4 weeks for the first 5 injections, then typically every 8 weeks, with some patients requiring continued monthly dosing if disease remains active.

Special administration instructions: Before each injection the eye is cleaned and numbed, a small needle is used to deliver the medicine into the vitreous, and the eye is checked afterward; if both eyes are treated, they are prepared and injected separately with new sterile equipment, and patients are usually advised not to rub the eye and to follow post-procedure instructions closely.

Missed dose guidance: If you miss a scheduled injection, contact your eye clinic as soon as possible to reschedule; do not attempt any self-injection or receive extra doses at the next visit to make up for a missed appointment.

Overdose: Overdose is uncommon because dosing is controlled by the clinician, but if excessive volume is injected it can raise eye pressure or cause other complications, so the eye will be monitored and treated promptly if any concerning symptoms occur.

Common side effects (often mild):

• Conjunctival hemorrhage (a small red patch on the white of the eye) that usually looks worse than it feels and resolves on its own.
• Eye pain, scratchiness, or irritation for a day or two after the injection.
• Cataract progression, new or increased floaters, vitreous detachment, or temporary increases in intraocular pressure after treatment.

Serious or rare adverse effects needing immediate care:

• Endophthalmitis (severe eye infection) or retinal detachment, which may cause increasing eye pain, redness, swelling, light sensitivity, sudden drop in vision, or a sudden shower of new flashes and floaters.
• Marked or persistent elevation of eye pressure, which can cause eye pain, headache, or blurred vision soon after the injection.
• Rare arterial thromboembolic events (such as stroke or heart attack) have been reported with intravitreal anti-VEGF therapy, particularly in patients with major vascular risk factors.

Warnings and precautions:

• Do not receive Pavblu if you have an active eye or periocular infection, active intraocular inflammation, or a known hypersensitivity to aflibercept or any component of the product.
• Pregnancy: Because VEGF inhibition can potentially harm a developing fetus, Pavblu should be used during pregnancy only if the potential benefit clearly justifies the potential risk; patients should discuss pregnancy planning and contraception with their eye specialist.
• Breastfeeding: Breastfeeding is generally not recommended during Pavblu treatment due to limited data on excretion into human milk and potential risk to the infant.
• Age limits: Pavblu is approved for adults; safety and effectiveness have not been established in children, and it is specifically not indicated for retinopathy of prematurity.
• Kidney or liver disease: No specific dose adjustments are defined, but patients with significant systemic disease should inform all of their clinicians so overall vascular risk can be considered.

Overall safety profile: As a biosimilar to Eylea 2 mg, Pavblu is expected to have a safety profile highly similar to Eylea and comparable to other intravitreal anti-VEGF agents, with most risks related to the injection procedure and class effects rather than to this specific brand.

Side-effect reporting and safety updates: Any new or worsening eye symptoms or systemic issues after an injection should be reported promptly to the treating eye specialist, and side effects can also be reported to the FDA through the MedWatch program (for example, by calling 1-800-FDA-1088 or using the online reporting system).

Drug and supplement interactions: Clinically important interactions with other medicines are unlikely because Pavblu is injected into the eye and reaches only very low levels in the bloodstream, but patients should still inform their ophthalmologist about all prescription drugs, over-the-counter medicines, blood thinners (such as warfarin, DOACs, or aspirin), and dietary or herbal supplements.

Food, alcohol, and lifestyle factors: No specific interactions with foods or alcohol have been identified for Pavblu; however, good control of blood pressure, blood sugar, and cardiovascular risk factors is important because underlying vascular disease can influence both eye disease and the small systemic risks of anti-VEGF therapy.

Other eye treatments and procedures: Combining Pavblu with other intravitreal injections, laser therapy, or eye surgery requires coordination; your ophthalmologist will schedule treatments to minimize the risk of infection, inflammation, and pressure spikes.

Conditions and co-medications that require caution:

• History of stroke, transient ischemic attack, heart attack, or uncontrolled hypertension, due to the theoretical increased risk of arterial thromboembolic events with anti-VEGF agents.
• Bleeding disorders or use of systemic anticoagulants, which may increase the chance of minor eye-surface bleeding after injections but usually do not contraindicate therapy.
• Any active ocular or periocular infection or significant intraocular inflammation, in which case Pavblu should be deferred until the condition has been treated.

Monitoring needs: At injection visits, clinicians typically check vision, examine the eye and retina, and measure intraocular pressure; over time, imaging tests such as optical coherence tomography (OCT) and regular dilated exams are used to track retinal fluid and guide adjustments to the dosing interval.

Q: How often will I need Pavblu injections?
A: Most people start with injections every 4 weeks for several months, then, if the eye is stable, the interval is usually extended to every 8 weeks and sometimes longer, with the exact schedule tailored to how your retina responds.

Q: Will Pavblu improve my vision or just stop it from getting worse?
A: Many patients have some improvement in vision and reduction in retinal swelling, especially in the first few months, but the main goal is to prevent further vision loss and maintain as much sight as possible over the long term.

Q: Is the Pavblu injection painful?
A: Your eye is numbed with drops or gel before the injection, so most people feel only brief pressure or a slight pinch, followed by mild scratchiness or irritation for a day or two.

Q: Can I drive after receiving Pavblu?
A: Vision is often blurred for several hours after the injection and exam, so you should plan for someone else to drive you home and avoid driving or operating machinery until your vision has cleared.

Q: How long will I need to stay on Pavblu treatment?
A: Retinal conditions such as wet AMD, RVO-related macular edema, and diabetic eye disease are usually chronic, so treatment is often long term, with your eye doctor gradually adjusting the injection interval or, in some cases, pausing therapy based on disease activity.